Targeting nucleolin-driven cancer stemness suppresses high-risk neuroblastoma in vivo
Dan Qi, Ronghu Ke, Euni Wu, Yizhong Pan, S. Stephen Yi, Jason H. Huang, Erxi Wu · 2027
Read Targeting nucleolin-driven cancer stemness suppresses high-risk neuroblastoma in vivo by Dan Qi, Ronghu Ke, Euni Wu, Yizhong Pan, S. Stephen Yi, Jason H. Huang, Erxi Wu (2027) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13553506.txt.
Description
Dan Qi and six colleagues target nucleolin-driven cancer stemness in high-risk neuroblastoma. Neuroblastoma is the most common solid tumor outside the brain in children, arising from developing nerve-lineage cells. High-risk disease makes up about half of cases and drives most deaths. Event-free survival for high-risk disease stays near 40 to 50 percent, and relapse is typically fatal.
Cancer stem cells in neuroblastoma renew themselves, seed tumors, and fuel spread, treatment resistance, and return of disease. The team's earlier work tied nucleolin to upkeep of CD34-positive stem cells. Their 2027 paper reports that targeting nucleolin-driven stemness suppresses high-risk neuroblastoma in living models. The work points to nucleolin as a lever against relapse and resistance.
Catalog record
| CREATOR | Dan Qi, Ronghu Ke, Euni Wu, Yizhong Pan, S. Stephen Yi, Jason H. Huang, Erxi Wu |
|---|---|
| YEAR | 2027 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |